Detalles de la búsqueda
1.
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.
Acta Derm Venereol
; 101(1): adv00354, 2021 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269405
2.
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
J Am Acad Dermatol
; 83(1): 139-150, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32213306
3.
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.
J Am Acad Dermatol
; 84(2): 513-517, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33122022
4.
Migratory, recurrent skin eruption in a returning traveller.
Australas J Dermatol
; 59(4): e307-e308, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29869372
5.
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.
J Dermatolog Treat
; 33(4): 2110-2117, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33913796
6.
Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.
J Dermatolog Treat
; 28(5): 401-405, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28001499
7.
SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept.
Acta Derm Venereol
; 90(5): 531-2, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20814638
8.
Vesicular Sézary syndrome with bullous lesions on the feet.
Eur J Dermatol
; 19(3): 282-3, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19258239
9.
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Arch Dermatol
; 148(4): 463-70, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22508869
Resultados
1 -
9
de 9
1
Próxima >
>>